Malaysia Infectious Disease Therapeutics Market Analysis

Malaysia Infectious Disease Therapeutics Market Analysis


$ 3999

By 2030, it is anticipated that the Malaysia infectious disease therapeutics market will reach a value of $275.12 Mn from $192.72 Mn in 2022, growing at a CAGR of 4.6% during 2022-2030. Infectious Disease Therapeutics in Malaysia is dominated by a few domestic pharmaceutical companies such as Pharmaniaga Berhad, Duopharma Biotech and Kotra Pharma. The Infectious Disease Therapeutics market in Malaysia is segmented into different therapeutic areas and different diseases type. The major factors affecting the Malaysia infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the amount of healthcare funding for infectious disease treatment in various areas of Malaysia.

ID: IN10MYPH038 CATEGORY: Pharmaceuticals GEOGRAPHY: Malaysia AUTHOR: Dr. Vishwa Modhia

Buy Now

Malaysia Infectious Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the Malaysia infectious disease therapeutics market will reach a value of $275.12 Mn from $192.72 Mn in 2022, growing at a CAGR of 4.6% during 2022-2030.

Malaysia, being an upper-middle-income, developing country, is a federation of 13 states and three federal territories in Southeast Asia. According to the World Factbook, Malaysia is extremely vulnerable to infectious illnesses. Food or waterborne infections include bacterial diarrhoea, hepatitis A and E, and typhoid fever.

Dengue fever is a vector-borne disease, and water-contact illnesses such as leptospirosis are frequent in Malaysia. Dengue fever is carried through the bite of pathogenic mosquitoes, and it affects a considerable proportion of Malaysia's population. from January to August 2021, the Malaysian government reported only a total of 16,565 dengue cases as opposed to 63,988 cases in 2020. The total number of dengue cases in the country has decreased by around 94%. Malaysia's government spends 4.1% of its GDP on healthcare.

Malaysia Infectious Disease Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers Analysis

The Malaysian Association for Tuberculosis Prevention (MAPTB) works hard to educate the public about TB prevention and to give financial assistance to diagnose and treat persons from high-risk categories. The COVID-19 pandemic has diverted attention away from the spread of other infectious illnesses around the world. However, the Malaysian government's fight against other infectious diseases has never halted. The government modified The Prevention and Manage of Infectious Diseases (Actions within Infected Local Areas) Regulations in March 2020 to better coordinate the measures it was adopted to control the COVID-19 pandemic and the transmission of other infectious diseases in Malaysia. These aspects could boost Malaysia's infectious disease therapeutics market.

Market Restraints

Malaysia used to receive considerable financial support from countries such as Japan, Denmark, and Germany in conjunction with the World Health Organization (WHO) until 1998. However, since 2000, the government has received little to no direct aid in the health sector. Many Malaysians may be unaware of the significance of infectious disease prevention and treatment, limiting demand for infectious disease medicines. Price competitiveness erosion in Malaysia due to rising labour costs might stymie corporate operations in the country. These factors may deter new entrants into the Malaysia infectious disease therapeutics market.

Competitive Landscape

Key Players

  • Pharmaniaga Berhad: Pharmaniaga is a pharmaceutical company based in Kuala Lumpur, Malaysia. The company develops and manufactures drugs for various diseases, including infectious diseases
  • Kotra Pharma (M) Sdn Bhd: Kotra Pharma is a pharmaceutical company based in Selangor, Malaysia. The company develops and manufactures drugs for various diseases, including infectious diseases
  • Hovid Berhad
  • Duopharma Biotech Berhad

Recent Notable Updates

December 2022: Pharmaniaga LifeScience, a wholly-owned subsidiary of Malaysia's leading pharmaceutical company, Pharmaniaga Berhad (Pharmaniaga), has committed to partner with BioNet-Asia on the development of a 6-in-1 Hexavalent Vaccine. The vaccine will provide Malaysian doctors with the best option for immunising children against six devastating childhood diseases. The programme will also help Malaysia achieve its objective of being vaccine self-sufficient by lowering reliance on importing life-saving vaccines and insulin from outside Malaysia. Furthermore, vaccine manufacture in-country will significantly improve vaccine security against future pandemic risks.

Healthcare Policies and Reimbursement Scenarios

In Malaysia, the Ministry of Health (MOH) and the national health insurance programme, known as the MySalam plan, are in charge of the regulation and reimbursement of infectious disease medicines. The MySalam plan, which provides financial protection to eligible Malaysians diagnosed with certain infectious diseases, has a big influence on the reimbursement process for infectious disease medicines in Malaysia.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Infectious Disease Therapeutics Segmentation

By Mode of Treatment (Revenue, USD Billion):

  • Vaccines
  • Drugs

By Applications (Revenue, USD Billion):

  • HIV/AIDS
  • Influenza
  • Hepatitis
  • Malaria
  • Tuberculosis
  • Others

By Disease Type (Revenue, USD Billion):

  • Viral Diseases
  • Bacterial Diseases
  • Fungal Diseases
  • Parasitic Diseases
  • Others

By Target Organism (Revenue, USD Billion):

  • Antibiotics
  • Antivirals
  • Antifungals
  • Anti-Parasitic
  • Others

By End User (Revenue, USD Billion):

  • Hospitals and Clinics
  • Ambulatory Care Centers
  • Others

Insights10 will provide you with the reports within 10 key parameters which are:

  1. Market Overview
  2. Market Growth Drivers & Restraints
  3. Epidemiology of Disease Type
  4. Market Segmentation
  5. Market Share
  6. Competitive Landscape
  7. Key Company Profiles
  8. Healthcare Policies & Regulatory Framework
  9. Reimbursement Scenario
  10. Factors Driving Future Growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

 

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

 

 

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and  Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.

We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.

 

 

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)

  • Establishing market drivers and trends
  • Analyzing the regulatory landscape to understand future growth
  • Market Segment based analysis to obtain revenue/volume
  • ​Analyzing current needs and determining penetration to estimate the market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.

Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.

The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.

By 2030, it is anticipated that the Malaysia infectious disease therapeutics market will reach a value of $275.12 Mn from $192.72 Mn in 2022, growing at a CAGR of 4.6% during 2022-2030.

In Malaysia, the regulation and reimbursement of infectious disease therapeutics are primarily overseen by the Ministry of Health (MOH) and the national health insurance program, the MySalam scheme.

Infectious Disease Therapeutics in Malaysia is dominated by domestic pharmaceutical companies such as Pharmaniaga Berhad, Duopharma Biotech and Kotra Pharma.


This report addresses

  • Intelligent insights to take informed business decisions
  • Qualitative, acute and result oriented market analysis
  • Market size and forecasts from 2022 to 2030
  • Opportunities for expansion and in-depth market analysis
  • Segmentation and regional revenue forecasts
  • Analysis of the market share and competitive landscape
  • Strategic Recommendations to chart future course of action
  • Comprehensive Market Research Report in PDF and PPT formats

Need more?

  • Ask our analyst how this study was put together to learn more
  • Discuss additional requirements as part of the free customisation
  • Add more countries or regions to the scope 
  • Get answers to specific business questions 
  • Develop the business case to launch the product
  • Find out how this report may influence your business revenue
Last updated on: 13 March 2023
Updated by: Ritu Baliya

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up